Luminary Therapeutics, Inc.

Based in Minnesota, US, and founded in 2019, Luminary Therapeutics, Inc. operates as a provider of CAR-T cell therapies using the Gamma 2. 0+ platform. The company has completed a single deal as of November 20, 2024, raising USD 5.

185 mn in its most recent funding round. The company was founded by Beau Webber and Jeff Liter, who led the company as CEO in 2025. Luminary Therapeutics offers CAR-T cell therapies, addressing challenges in treating both solid tumors and hematological malignancies. Their core product offerings include an allogenic CAR design platform, which incorporates a Dual CAR architecture allowing for the targeting of multiple cancer antigens simultaneously.

 The company’s therapies are designed for patients suffering from B-cell malignancies and specific B-cell mediated autoimmune diseases. Luminary's products primarily serve healthcare providers, hospitals, and oncology clinics across various geographical markets, including North America and Europe, where the demand for cancer therapies continues to grow.   Luminary Therapeutics generates revenue through strategic partnerships with healthcare institutions and direct sales of its CAR-T cell therapy products. The company's business model typically involves collaborations with oncology clinics and hospitals, where they provide their innovative cellular therapies in exchange for service fees or licensing agreements.

This partnership structure allows Luminary to maintain control over its proprietary technologies while expanding its client base within the oncology sector. Revenue is derived from transactional frameworks that include per-treatment fees or milestone payments associated with the successful administration of their therapies. The firm focuses on delivering cost-effective solutions that mitigate financial strain for both patients and healthcare providers, reinforcing its commitment to accessible cancer treatment.